ProQR Therapeutics NV (PRQR)
2.38
-0.05
(-2.06%)
USD |
NASDAQ |
Aug 25, 16:00
2.365
-0.02
(-0.63%)
After-Hours: 19:59
ProQR Therapeutics Shareholders Equity (Quarterly) : 90.87M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 90.87M |
| March 31, 2026 | 43.32M |
| December 31, 2025 | 57.99M |
| September 30, 2025 | 67.06M |
| June 30, 2025 | 78.63M |
| March 31, 2025 | 85.27M |
| December 31, 2024 | 91.70M |
| September 30, 2024 | 27.88M |
| June 30, 2024 | 35.21M |
| March 31, 2024 | 37.61M |
| December 31, 2023 | 45.72M |
| September 30, 2023 | 49.06M |
| June 30, 2023 | 56.50M |
| March 31, 2023 | 64.11M |
| December 31, 2022 | 71.58M |
| September 30, 2022 | 63.60M |
| June 30, 2022 | 91.34M |
| March 31, 2022 | 112.19M |
| December 31, 2021 | 129.45M |
| September 30, 2021 | 149.05M |
| June 30, 2021 | 140.06M |
| March 31, 2021 | 58.45M |
| December 31, 2020 | 69.85M |
| September 30, 2020 | 80.47M |
| June 30, 2020 | 89.96M |
| Date | Value |
|---|---|
| March 31, 2020 | 89.83M |
| December 31, 2019 | 105.88M |
| September 30, 2019 | 65.27M |
| June 30, 2019 | 80.44M |
| March 31, 2019 | 91.10M |
| December 31, 2018 | 106.22M |
| September 30, 2018 | 119.14M |
| June 30, 2018 | 26.70M |
| March 31, 2018 | 36.34M |
| December 31, 2017 | 47.27M |
| September 30, 2017 | 38.72M |
| June 30, 2017 | 41.95M |
| March 31, 2017 | 48.92M |
| December 31, 2016 | 56.05M |
| September 30, 2016 | 69.04M |
| June 30, 2016 | 78.80M |
| March 31, 2016 | 91.39M |
| December 31, 2015 | 97.55M |
| September 30, 2015 | 106.75M |
| June 30, 2015 | 113.25M |
| March 31, 2015 | 118.07M |
| December 31, 2014 | |
| September 30, 2014 | 140.48M |
| June 30, 2014 | 46.58M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Pharming Group NV | 257.03M |
| NewAmsterdam Pharma Co. NV | 631.42M |
| argenx SE | -- |
| Mirum Pharmaceuticals, Inc. | -10.42M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 152.69M |
| Total Liabilities (Quarterly) | 61.83M |
| Debt to Equity Ratio | 0.166 |
| Current Ratio | 3.488 |
| Net Debt Paydown Yield | 0.09% |